OncoVEXmGM-CSFexpands tumor antigen-specific CD8+ T-cell response in preclinical models
Sign Up to like & getrecommendations! Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-006374
Abstract: Background Checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) have demonstrated clinical efficacy in advanced melanoma, but only a subset of patients with… read more here.
Keywords: cell; csf; oncovexmgm csf; checkpoint ... See more keywords